$92.98
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Country

DE

CEO

Prof. Ugur Sahin

IPO date

2019

Employees

7,807

ISIN

US09075V1026

Key stats

Open

$93.31

Volume

816.25K

Market cap

$27.24B

Prev. close

$92.98

Impl / hst vl

-

Open interest

$0.00

$92.36

Day’s Range

$94.62

$79.52

52W Range

$124.00

Valuation

50
Valuation score
Fairly Valued
P/E
-
P/S
8.21
P/B
1.12
Current ratio
8.80
Debt / Equity
-0.52
ROE
-6.69%
Gross margin
40.47%
Income growth
74.39%
FCF growth
-302.06

Jun

17

Dividends

The last payment date was Jun 17, 2022

Div. per Share

$2.44

Div. Yield

2.28%

Payout Ratio

-

Div. Growth YoY

-

Analysts estimates

Consensus rating
Buy

The average rating from top 16 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$130.56
The top 24 analysts forecasts that 12-month price may increase by 40.42%, with a low of $85.85 and a high of $190.05
$85.85
Low
$130.56
Avg
$190.05
High
Current price

Earnings

Q1 ‘26 revenue
$134.91M
Q1 ‘26 net income
-$607.61M
Revenue
Net income
Previous EPS
-$2.40
Estimate EPS
-$2.45
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply